Curapath is pleased to acknowledge the significant progress achieved by Macro Biologics, Inc., whose IND application for Amicidin‑α Surgical Gel has been accepted by the FDA, enabling the initiation of the Phase 1 clinical trial. This milestone marks a decisive step in the evolution of the Amicidin‑α platform toward clinical
Curapath has partnered with Nacalai Tesque to expand access to its portfolio of next-generation polymers and PEG-free shielding lipids for advanced drug delivery applications in Japan. This collaboration strengthens Curapath’s global presence and enables local availability of high-quality excipients for researchers and biopharma companies working on non-viral delivery technologies. Through
Over the past two decades, polymer-based drug delivery systems have evolved from experimental concepts to clinically validated technologies, playing a key role in the development of next-generation therapeutics. At Curapath, with over 13 years of hands-on expertise, we support biotech and pharmaceutical companies with polymer and lipid-based solutions, from early
At Curapath, we are committed to pushing the boundaries of polymer and lipid-based drug delivery. Today, we are excited to share that we have entered into a co-exclusive license agreement with Cristal Therapeutics to integrate their groundbreaking CliCr® bioconjugation platform into our technology and service portfolio. CliCr® provides a powerful,
Curapath is proud to announce the renewal of its Crédit Impôt Recherche (CIR)accreditation up to 2027. Granted by the French Ministry of Higher Education and Research, this accreditationallows French companies collaborating with Curapath to continue benefiting from theR&D tax credit on eligible research and development expenditures.The Crédit Impôt Recherche program
Curapath, a leading innovator in the design and manufacturing of polymer and lipid-based drug delivery systems, is proud to announce a strategic partnership with Iris Biotech, a global distributor of specialty reagents for drug development and delivery. Through this collaboration, Iris Biotech will offer a broad selection of Curapath’s proprietary
NanoThera Summit 2025: An event that consolidates Valencia as a key hub for innovation in nanotherapies and advanced Therapies Valencia, September 2025 The inaugural edition of NanoThera Summit has been a complete success, establishing Valencia as a global benchmark in the fields of nanotherapies, advanced drug delivery, and gene therapy.
Curapath is gearing up for a busy season of innovation, networking, and collaboration. Over the next few months, our team will be present at some of the world’s leading biotech and pharmaceutical conferences, connecting with partners, sharing insights, and showcasing our latest advances in drug delivery technologies. Here’s where you’ll
Curapath has entered into an exclusive license agreement with Calusa Bio, LLC, further strengthening its PEG alternative toolbox with a novel and differentiated technology. This strategic addition enhances our ability to advance PEG-free delivery systems for biologics, peptides, and nucleic acids in next-generation therapies. By combining Curapath’s expertise in PEG-free
VALENCIA, SPAIN, SEPTEMBER 2, 2025 At Curapath, our mission has always been to push the boundaries of non-viral drug delivery. Today, we are proud to announce a strategic partnership with Cayman Chemical that will make our proprietary PEG-free shielding lipids more accessible to researchers worldwide. Through Cayman’s extensive global distribution
